Lisdexamfetamine Dimesylate · #29 of 35 active shortages by FDA posting duration
Brand: LISDEXAMFETAMINE DIMESYLATE
FDA lists Lisdexamfetamine Dimesylate as Active Shortage (Hikma Pharmaceuticals USA, Inc.).
Availability on file: Limited Availability
Lisdexamfetamine Dimesylate Capsule: Active Shortage
Limited Availability 108 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Lisdexamfetamine Dimesylate Capsule
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Dosage Form
- Capsule
- Presentation
- Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)
- Package NDC
- 0054-0372-25
Status & Timeline
- Status
- Active Shortage
- Availability
- Limited Availability
- First Reported
- Jul 14, 2023
- Last Updated
- Mar 12, 2026
- Therapeutic Category
- Psychiatry
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Available on allocation
Full Drug Profile
lisdexamfetamine
Side effects, interactions, warnings & more
Nearby, Other Lisdexamfetamine Shortage Records
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
Lisdexamfetamine Dimesylate Capsule
Rhodes Pharmaceuticals L.P.
Capsule
FDA reason on file: Available on allocation. General shortage guidance lives on the tracker hub.